
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem is a promising investment opportunity as its late-stage development in biopharmaceuticals, specifically in targeting signaling pathways in cancer cells, could lead to potentially significant long-term growth. With a strong pipeline and recent earnings report showing a revenue miss due to seasonality and early stage patients, the company is focused on ramping up commercial efforts and has a healthy amount of cash for continued research and development. The upcoming data releases for VS-7375 and RAMP 205 could offset any short-term turbulence and highlight the potential for substantial peak sales, while partnerships for commercialization and the potential for combination regimens further support the company's growth potential.
Bears say
Verastem is heavily dependent on the success of their two main programs, RAMP 205 and GenFleet, which are still in early stages of development. While initial data for both programs showed promising response rates, it is unclear if these results can be replicated in larger patient populations, and management's ORR goal of ≥50% may be overly ambitious. Furthermore, the company has yet to report any significant revenue and is burning through its cash reserves, making it a high-risk investment.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares